Interestingly, compound 76b is the most effective hCA II activator (KA 0.05 nM) ever reported, and has shown to be a lead compound for the development of clinical candidates in cognitive impairment or other diseases characterized by a deficit of hCA I and hCA II isoforms, such as Alzheimer’s disease or aging [67]. The gene discussed is CYP24A1; the disease is early-onset autosomal dominant Alzheimer disease.